Credit Rating
Anupam Rasayan Placed on CRISIL ‘Watch Developing’ Following Proposed Bliss GVS Pharma Acquisition
NSE
anuras
BSE
543275
Anupam Rasayan India Limited informed exchanges that CRISIL Ratings has placed its credit ratings on “Rating Watch with Developing Implications” following the proposed acquisition of a 43.3%–48.2% stake in Bliss GVS Pharma. The rating agency will assess the final funding structure, leverage impact, and regulatory approvals before resolving the watch status.
PRICE-SENSITIVE TRIGGER
Event: CRISIL revises ratings outlook and places ratings on Watch Developing.
Type: Credit Rating
Impact: Neutral
Immediate Effect: The company retains investment-grade ratings; however, future rating action will depend on acquisition funding, debt levels, and transaction completion.
Key Metrics:
- Total Bank Facilities Rated: ₹1,620 crore (enhanced from ₹1,369.82 crore)
- Long-Term Rating: CRISIL A+/Watch Developing
- Short-Term Rating: CRISIL A1/Watch Developing
- Non-Convertible Debentures: ₹160 crore rated CRISIL A+/Watch Developing
- FY26 Operating Income: ₹2,365.46 crore
- FY25 Operating Income: ₹1,438.72 crore
- FY26 PAT: ₹222.20 crore
- FY25 PAT: ₹159.85 crore
- FY26 PAT Margin: 9.39%
- FY25 PAT Margin: 11.11%
Highlight:
- CRISIL placed all key ratings on Watch Developing after the announced acquisition of Bliss GVS Pharma, citing uncertainty around the final funding mix and leverage profile.
What Happened ?
Anupam Rasayan informed stock exchanges that CRISIL Ratings has revised its rating outlook by placing the company’s ratings on “Rating Watch with Developing Implications.”
The action follows the company’s proposed acquisition of a significant stake in Bliss GVS Pharma. CRISIL indicated that the final rating outcome will depend on the transaction structure, funding mechanism, regulatory approvals, and resulting financial profile.
Key Details
Rating Action & Acquisition Context:
- CRISIL enhanced rated bank facilities to ₹1,620 crore.
- Long-term facilities continue to carry CRISIL A+ rating with Watch Developing status.
- Short-term facilities carry CRISIL A1 rating with Watch Developing status.
- ₹160 crore NCD issue assigned CRISIL A+/Watch Developing.
- Rating action follows the proposed acquisition of 43.3%–48.2% equity stake in Bliss GVS Pharma.
- Acquisition funding is expected through a combination of debt and equity.
- Company has indicated debt funding of approximately ₹300 crore.
- CRISIL expects any eventual rating movement to remain limited, subject to funding clarity.
- FY26 revenue growth was supported by agrochemical, pharma, and polymer segments.
- Working capital cycle improved through lower inventory and receivable days.
Note:
- CRISIL will continue monitoring transaction developments and funding arrangements before removing the Watch Developing status.
Risk Analysis
Summary:
- The rating watch reflects uncertainty around acquisition financing and the impact on leverage, rather than deterioration in current operating performance.
Key Risks:
- Higher debt funding may increase leverage.
- Regulatory approvals remain pending.
- Acquisition integration risks could emerge after completion.
- Working-capital intensity remains elevated.
- Exposure to foreign exchange fluctuations continues due to export dependence.
- Margin volatility remains linked to raw material pricing movements.
Worst Case Scenario:
- If the acquisition is funded with materially higher debt than anticipated or if financial metrics weaken post-acquisition, the company could face a negative rating action after review.
Risk Level: Medium
Company Commentary
- The company has informed exchanges of the revised CRISIL rating action.
- CRISIL continues to recognize Anupam Rasayan’s strong market position and diversified specialty chemicals portfolio.
- The company maintains healthy business linkages across its subsidiaries and acquired entities.
- Growth continues to be supported by pharma, fluorination chemistry, polymer, and specialty chemical segments.
- Management remains focused on expanding higher-value specialty chemical and pharmaceutical opportunities.
Official Exchange Filing: Anupam Rasayan India Limited